Adolor

Cubist acquires Adolor in an agreement worth $415 million

Monday, October 24, 2011

Cubist Pharmaceuticals and Adolor have signed a definitive agreement under which Cubist will acquire all of the outstanding shares of Adolor for approximately $190 million on a fully-diluted basis, net of Adolor’s third quarter 2011 cash balance. The total transaction is valued at up to $415 million, net of Adolor’s third quarter 2011 cash balance, and is expected to be accretive in 2012.

[Read More]